#FDA approval

Lurbinectedin shrank tumors in a third of people with this less common type of lung cancer.

These are the latest cancer treatments approved by the FDA.

Checkpoint inhibitor extended survival by about three months compared with chemotherapy.

Ramucirumab slowed disease progression more than a placebo when added to erlotinib.

Study showed 74% overall response rate for people who used brigatinib as their first ALK inhibitor.

New targeted therapy delayed disease progression compared with a placebo.

Initial treatment with atezolizumab led to longer overall survival in people with high biomarker levels.

The combination led to improved overall survival compared with chemotherapy.

The immune-modulating drug was approved to treat the rare cancer in HIV-positive and HIV-negative people.

Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.

The PARP inhibitor delayed disease progression by 20 months compared with a placebo.

Capmatinib shrank tumors in 68% of people with metastatic non-small-cell lung cancer with a specific MET mutation.

A study of melanoma patients found that treatment every six weeks is comparable to every three weeks.

Darzalex Faspro can be given by subcutaneous injection rather than IV infusion.

Zejula delayed disease progression in people with advanced ovarian cancer who had a complete or partial response to platinum chemotherapy.